HOPA 2025: Understanding the Recent Changes for 505(b)(2) Drugs and Reimbursement
April 12th 2025Scott A. Soefje, PharmD, MBA, BCOP, explained how the expanding use of the FDA’s 505(b)(2) drug approval pathway is creating operational and reimbursement challenges for oncology infusion centers.
Read More